Assenagon Asset Management S.A. Protagonist Therapeutics, Inc Transaction History
Assenagon Asset Management S.A.
- $54.1 Billion
- Q4 2024
A detailed history of Assenagon Asset Management S.A. transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Assenagon Asset Management S.A. holds 52,239 shares of PTGX stock, worth $2.02 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
52,239Holding current value
$2.02 Million% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding PTGX
# of Institutions
254Shares Held
58.9MCall Options Held
189KPut Options Held
191K-
Farallon Capital Management LLC San Francisco, CA5.93MShares$229 Million1.22% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$223 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.5MShares$213 Million3.46% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.22MShares$163 Million0.0% of portfolio
-
State Street Corp Boston, MA3.33MShares$129 Million0.01% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $1.9B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...